Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing
CNS Experts Hired As Contera Built Out
Executive Summary
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
You may also be interested in...
Bukwang Acquires Acer Stake In Pattern Of Venture Investments
Bukwang Pharm has purchased a minority stake in U.S. bioventure Acer Therapeutics, which is seeking to list its shares on Nasdaq early next year. The investment is the sixth the South Korean firm has made together with TVM Life Science Capital to gain investment returns and beef up R&D.
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
GC LabCell Taps Alliances In Bid For Lead NK Cell Position
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.
Need a specific report? 1000+ reports available
Buy Reports